Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- NIID, ID Pharma to Collaborate on Research for Therapeutic Vaccines for AIDS
April 16, 2015
- Nesina’s Cardiovascular Profile Acceptable: FDA Advisory Panel
April 16, 2015
- Lixiana Gains Swiss Nod, First Approval in Europe: Daiichi Sankyo
April 16, 2015
- MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
- Hisamitsu Initiates PIII Study of Transdermal Parkinson’s Disease Treatment Ropinirole in Japan
April 16, 2015
- Eisai to Collaborate with Genomics for Drug Discovery
April 14, 2015
- Japan CSO Association Aims to Double No. of Contract Sales Reps to 8,000 by FY2020
April 14, 2015
- ViiV Healthcare Launches HIV Treatment Triumeq Combination Tablets
April 13, 2015
- Japan Vaccine Files NDA for Intradermal Influenza Vaccine
April 13, 2015
- Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
- Ethical Drug Sales Down 1.4% in February: Crecon Report
April 10, 2015
- IFN-Free, All Oral Treatment for Hepatitis C Demonstrates Impressive Response Rate
April 10, 2015
- Livalo Shows No Negative Effects on Fasting Blood Glucose Levels, HbA1c: Kowa
April 10, 2015
- Regience Partners with Keio Univ. for Joint Research of Liver Regeneration
April 10, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
April 9, 2015
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
- Hisamitsu Sales Up 4.1% despite Dull Japan Biz, Mohrus Down 8.5%
April 9, 2015
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
- Bayer Yakuhin Negotiating with Universities, Institutions for Research Agreements
April 9, 2015
- Merck KGaA, Pfizer to Copromote Xalkori in Japan, US, Europe
April 9, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…